A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy.

Trial Profile

A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2013

At a glance

  • Drugs Temsirolimus (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms INTORSECT
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 02 Dec 2013 Results published in the Journal of Clinical Oncology.
    • 03 Jul 2013 Planned number of patients changed from 501 to 508 as reported by German Clinical Trials Register.
    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004149).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top